Literature DB >> 19713141

Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells.

Y Saitoh1, W Hongwei, H Ueno, M Mizuta, M Nakazato.   

Abstract

AIM: Angiotensin II receptor blockers (ARB) have been shown to lower insulin resistance in obese diabetic animal models and to reduce the risk of new-onset diabetes in hypertensive patients. In the present study, we studied whether telmisartan, an ARB with partial peroxisome proliferator-activated receptor-gamma (PPARgamma) activity, can exert a direct effect against fatty-acid-induced oxidative stress in pancreatic beta-cells.
METHODS: The effect of telmisartan on lipotoxicity was evaluated using mouse insulin-secreting clonal MIN6 and isolated mouse pancreatic islet cells. Reactive oxygen species, protein kinase-C (PKC) activity and NAD(P)H oxidase activity were examined to clarify the underlying mechanisms. RESULT: Telmisartan decreased the accumulation of palmitate-induced reactive oxygen species in MIN6 cells by 25% and in mouse islet cells by 55%. Telmisartan also decreased palmitate-induced PKC activity by 36% and NAD(P)H oxidase activity by 32% in MIN6 cells.
CONCLUSION: These findings indicate that telmisartan attenuated fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Our observations pave the way to the possible use of ARB as a means of protecting beta-cell survival and preserving insulin secretion capacity in patients with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19713141     DOI: 10.1016/j.diabet.2009.04.005

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  12 in total

Review 1.  Oxidative stress and beta-cell dysfunction.

Authors:  Gisela Drews; Peter Krippeit-Drews; Martina Düfer
Journal:  Pflugers Arch       Date:  2010-07-23       Impact factor: 3.657

Review 2.  Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy.

Authors:  George Bayliss; Larry A Weinrauch; John A D'Elia
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

Review 3.  The role of renin-angiotensin agents in altering the natural history of type 2 diabetes mellitus.

Authors:  Joel A Lardizabal; Prakash C Deedwania
Journal:  Curr Cardiol Rep       Date:  2010-11       Impact factor: 2.931

4.  The protective effect of telmisartan in Type 2 diabetes rat kidneys is related to the downregulation of thioredoxin-interacting protein.

Authors:  J Wu; H Lin; D Liu; J Liu; N Wang; X Mei; J Sun; G Yang; X Zhang
Journal:  J Endocrinol Invest       Date:  2012-11-27       Impact factor: 4.256

Review 5.  Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.

Authors:  Bodh I Jugdutt
Journal:  Clin Interv Aging       Date:  2010-12-03       Impact factor: 4.458

6.  Diabetic microvascular complications: possible targets for improved macrovascular outcomes.

Authors:  John A D'Elia; George Bayliss; Bijan Roshan; Manish Maski; Ray E Gleason; Larry A Weinrauch
Journal:  Int J Nephrol Renovasc Dis       Date:  2010-12-22

Review 7.  The impact of age-related dysregulation of the angiotensin system on mitochondrial redox balance.

Authors:  Ramya Vajapey; David Rini; Jeremy Walston; Peter Abadir
Journal:  Front Physiol       Date:  2014-11-24       Impact factor: 4.566

8.  Reversal of angiotensin ll-induced β-cell dedifferentiation via inhibition of NF-κb signaling.

Authors:  Hong Chen; Wenjun Zhou; Yuting Ruan; Lei Yang; Ningning Xu; Rongping Chen; Rui Yang; Jia Sun; Zhen Zhang
Journal:  Mol Med       Date:  2018-08-14       Impact factor: 6.354

9.  Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice.

Authors:  Asuka Shiota; Michio Shimabukuro; Daiju Fukuda; Takeshi Soeki; Hiromi Sato; Etsuko Uematsu; Yoichiro Hirata; Hirotsugu Kurobe; Norikazu Maeda; Hiroshi Sakaue; Hiroaki Masuzaki; Iichiro Shimomura; Masataka Sata
Journal:  Cardiovasc Diabetol       Date:  2012-11-08       Impact factor: 9.951

10.  Prevalence of diabetic nephropathy in Type 2 Diabetes Mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment.

Authors:  Priscyla Zenteno-Castillo; Daniela Beatriz Muñoz-López; Benjamín Merino-Reyes; Ángel Vega-Sánchez; Monica Preciado-Puga; Ana Lilia González-Yebra; Carlos Kornhauser
Journal:  J Clin Transl Endocrinol       Date:  2015-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.